慢性乙型肝炎病毒感染治疗对患者报告结局的影响
该研究分析了2项国际2期盲法对照试验中242例无晚期纤维化或肝硬化的慢性HBV感染患者的PRO数据,患者接受批准的口服抗病毒方案后随机加用vesatolimod或安慰剂。vesatolimod与安慰剂组PRO无显著差异;治疗期间部分CLDQ域和SF-36总体健康评分显著升高(最高4.9%,P<.05),HBV DNA下降≥2.7 log10 IU/mL者PRO升高更明显。
要点
- vesatolimod与安慰剂组患者报告结局无显著差异。
- 治疗期间部分CLDQ域和SF-36总体健康评分显著升高,最高4.9%(P<.05)。
- HBV DNA下降≥2.7 log10 IU/mL者PRO升高更明显,22项PRO中10项P<.05。
核心结论
- 在2期试验数据分析中,慢性HBV感染的积极治疗与PRO评分升高相关。
- 这些发现支持在HBV感染治疗临床试验的疗效和安全性评估中纳入PRO终点。
研究设计与样本
- 收集并分析2015年至2017年纳入2项国际2期盲法对照临床试验的242例无晚期纤维化或肝硬化的慢性HBV感染患者的PRO数据。
- 患者接受批准的口服抗病毒方案(替诺福韦、恩替卡韦、阿德福韦、拉米夫定或替比夫定)治疗,随后随机分配至vesatolimod组(口服Toll样受体7激动剂)或安慰剂组。
- 使用Short Form-36、慢性肝病问卷和工作生产力与活动障碍:特定健康问题问卷在治疗前及治疗第12、24、48周收集PRO。
主要发现
- vesatolimod组与安慰剂组患者的PRO无显著差异。
- 基线时,病毒抑制(HBV DNA水平<20 IU/mL)患者的PRO评分更高(最高达PRO范围大小的+10.6%)。
- 治疗期间,慢性肝病问卷部分域评分和Short Form-36总体健康评分显著升高(升高最高达4.9%;P<.05)。
- HBV DNA水平下降至少2.7 log10 IU/mL的患者PRO评分升高幅度更大(22项研究的PRO中10项P<.05)。
- 多变量分析中,病毒载量下降与PRO升高独立相关(β值最高为每log10 IU/mL下降1.6%;P<.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic infection with hepatitis B virus (HBV) causes liver disease and cirrhosis. It is not clear how treatment of chronic HBV infection affects patient-reported outcomes (PROs). We aimed to assess changes in PROs in patients treated for chronic HBV infection. METHODS: We collected and analyzed PRO data from 242 patients with chronic HBV infection (without advanced fibrosis or cirrhosis) enrolled in 2 international phase 2 blinded controlled clinical trials from 2015 through 2017. In these trials, patients were treated with an approved oral antiviral regimen (tenofovir, entecavir, adefovir, lamivudine, or telbivudine) and then randomly assigned to groups given vesatolimod (an oral agonist of Toll-like receptor 7) or placebo. PROs were collected using the Short Form-36, the Chronic Liver Disease Questionnaire, and the Work Productivity and Activity Impairment: Specific Health Problem questionnaires before treatment and during treatment weeks 12, 24, and 48. RESULTS: We did not observe significant differences in PROs between patients receiving vesatolimod vs placebo. At baseline, patients with viral suppression (HBV DNA level, <20 IU/mL) had higher PRO scores (by up to +10.6% of a PRO range size). During treatment, there were significant increases in scores for some domains of the Chronic Liver Disease Questionnaire and in General Health scores of Short Form-36 (increases of up to 4.9%; P < .05). Patients with a decrease of at least 2.7 log10 IU/mL in level of HBV DNA had substantially larger increases in PRO scores (P < .05 for 10 of 22 studied PROs). In multivariate analysis, a reduction in viral load was independently associated with increases in PROs (β values up to 1.6% per log10 IU/mL decrease; P < .05). CONCLUSIONS: In an analysis of data from phase 2 trials, we associated active treatment of chronic HBV infection with increased PRO scores. These findings support inclusion of PRO end points in assessments of efficacy and safety in clinical trials of treatments for HBV infection.
引用
- Younossi ZM, Stepanova M, Janssen HLA, et al. Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. Clin Gastroenterol Hepatol. 2018. PMID: 29505905. doi:10.1016/j.cgh.2018.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。